Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-175-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- Gastroplus modelling of repeated oral exposure to rats for 90 days
- Type of information:
- other: In silico predictive model
- Adequacy of study:
- key study
- Study period:
- April-July 2020
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Justification for type of information:
- Information on oral absorption and other major pharmacokinetic parameters is provided in support of data waiving arguments for in vitro micronucleus assay and repeat dose oral toxicity studies
- Objective of study:
- bioaccessibility (or bioavailability)
- Principles of method if other than guideline:
- For the predictions of Fa%, F%, Css, and AUC 0-2160 hr of the representative major components of PRIMENE 81-R following 90-day repeated dietary exposures in rats, a PBPK model was utilized in GastroPlus (version 9.7). This PBPK model contains 13 compartments (lung, adipose, muscle, liver, spleen, heart, brain, kidney, skin, reproductive organs, red marrow, yellow marrow, and the rest of the body). In this PBPK simulation, the oral dose formulation type was defined to be a suspension (equivalent to the dietary type in the defined PBPK model) with particle size of 25 μm mean radius
- GLP compliance:
- not specified
- Specific details on test material used for the study:
- Not applicable - method is an in silico predictive model
- Radiolabelling:
- no
- Species:
- other: Not applicable - in silico rat model
- Strain:
- not specified
- Remarks:
- In silico rat model
- Details on species / strain selection:
- Not applicable - report is an in silico rat model of gastric absorption
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- Not applicable - report is an in silico rat model of gastric absorption
- Route of administration:
- not specified
- Vehicle:
- not specified
- Remarks:
- Not applicable - report is an in silico rat model of gastric absorption
- Details on exposure:
- Not applicable - report is an in silico rat model of gastric absorption
- Duration and frequency of treatment / exposure:
- Not applicable - report is an in silico rat model of gastric absorption
- No. of animals per sex per dose / concentration:
- Not applicable - report is an in silico rat model of gastric absorption
- Control animals:
- not specified
- Executive summary:
PRIMENE™ 81-R (Amines, C10-C14-tert-Alkyl) is a mixture containing major components with alkyl carbon number ranged from C10 to C14. Experimental data on oral absorption in rats either from single or repeated oral exposures (such as repeated 90-day dietary exposure) is not available for this mixture. Therefore, the oral bioavailability, other major pharmacokinetic parameters, and metabolic clearance data of the major representative 20 components of the mixture were estimated via the widely accepted QSAR programs, ADMET predictor (v9.5, Simulations Plus Inc, Lancaster, CA, USA), and GastroPlus (v9.7, Simulations Plus Inc, Lancaster, CA, USA).
Using the parameters for a repeated 90-day oral dietary exposure to a fed rat (0.25 kg) at dose level of 107 mg/kg/day (mkd), the predicted fractional absorption (Fa%), bioavailability (F%), and maximum steady-state plasma concentration (Css ), area under curve (AUC) values, and rat liver microsomal clearance (CYP-RLM-CLint) of the representative 20 components by GastroPlus were determined.
Overall, the predicted Fa%, F%, Css, AUC, and CYP-RLM-CLint for these major components were in the ranges of 97.60-99.81%, 16.10-34.97%, 0.646-1.092 μg/mL, 493-999 μg.h/mL, and 196.602-435.343 μl/min/mg RLM protein, respectively.
According to the predicted values of Fa%, F%, Css, and AUC, all these representative components of PRIMENE 81-R are bioavailable in rats, and the predicted CYP-RLM-CLint values indicate that all these representative components can be metabolized via cytochrome p450 (CYP). The predicted plasma time-courses of the representative components indicated no apparent bioaccumulation of any of the representative major components of PRIMENE 81-R upon repeated-day exposures at the dose level of 107 mkd.
Reference
Description of key information
PRIMENE™ 81-R (Amines, C10-C14-tert-Alkyl) is a mixture containing major components with alkyl carbon number ranged from C10 to C14. Experimental data on oral absorption in rats either from single or repeated oral exposures (such as repeated 90-day dietary exposure) is not available for this mixture. Therefore, the oral bioavailability, other major pharmacokinetic parameters, and metabolic clearance data of the major representative 20 components of the mixture were estimated via the widely accepted QSAR programs, ADMET predictor (v9.5, Simulations Plus Inc, Lancaster, CA, USA), and GastroPlus (v9.7, Simulations Plus Inc, Lancaster, CA, USA).
Using the parameters for a repeated 90-day oral dietary exposure to a fed rat (0.25 kg) at dose level of 107 mg/kg/day (mkd), the predicted fractional absorption (Fa%), bioavailability (F%), and maximum steady-state plasma concentration (Css ), area under curve (AUC) values, and rat liver microsomal clearance (CYP-RLM-CLint) of the representative 20 components by GastroPlus were determined.
Overall, the predicted Fa%, F%, Css, AUC, and CYP-RLM-CLint for these major components were in the ranges of 97.60-99.81%, 16.10-34.97%, 0.646-1.092 μg/mL, 493-999 μg.h/mL, and 196.602-435.343 μl/min/mg RLM protein, respectively.
According to the predicted values of Fa%, F%, Css, and AUC, all these representative components of PRIMENE 81-R are bioavailable in rats, and the predicted CYP-RLM-CLint values indicate that all these representative components can be metabolized via cytochrome p450 (CYP). The predicted plasma time-courses of the representative components indicated no apparent bioaccumulation of any of the representative major components of PRIMENE 81-R upon repeated-day exposures at the dose level of 107 mkd.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 97.6
Additional information
No data are available for the toxicokinetics of the test material in human and non-human species. Information on other primary alkylamines [C8 (1-octanamine), C10 (1-decanamine) and C12 (1-dodecanamine)- ] are useful to understand the expected toxicokinetic behavior of teh test material because they are of similar alkyl chain length and functionality.
The test material is expected to be well absorbed by all exposure routes. Following absorption, initial distribution parallels perfusion. Alkylamines are oxidatively deaminated by monoaminooxidases with concomitant formation of ammonia and the corresponding alkylamine aldehyde. Oxidative deamination decreases with increasing carbon chain length. Subsequently, the aldehydes are oxidised by aldehyde dehydrogenases to the corresponding carboxylic acids, which, in turn, are further metabolised by ß-oxidation. Carbon dioxide as a product from ß-oxidation is exhaled. Urinary excretion is a minor elimination pathway.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
